Skip to main content

Appelhans Dannielle's Form 4 filing

Rubius Therapeutics, Inc. (RUBY) · filed Aug 12, 2022

Accession no.
0001709401-22-000016
Filed
Aug 12, 2022
Trade date
Aug 9-10, 2022
Filing delay
3 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $4.59K. It was filed 3 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Appelhans DannielleCIK 0001874962Officer (Chief Operating Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 9, 2022Common StockMOption exerciseAcquired+12,500–F1–12,500Direct
Aug 10, 2022Common StockSSaleDisposed−5,737$0.80−$4,589.66,763Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 9, 2022Common StockMOption exerciseDisposed−12,500$0.00$037,500Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)